Company logo
Get Listed

New Treatment For Esophageal Cancer 2022 - FDA Approved

Esophageal cancer is the 8th most common form of cancer. However, there have been continuous advancement in new treatment for esophageal cancer. Read on to know the latest updates of 2022.

  • Cancer

By Aranya Doloi

12th Oct '22

Blog Banner Image

Esophageal cancer is a form of common gastrointestinal malignancy that originates in the esophagus. There are two most common types of esophageal cancer:

  • Adenocarcinoma
  • Squamous cell carcinoma 

Adenocarcinoma occurs closer to the stomach. On the other hand, squamous cell carcinoma occurs mainly in the upper part of the esophagus. 

Esophageal cancer is the 8th most commonly diagnosed form of cancer worldwide. As per reports, it is the 13th most common cancer among women and the 7th most common type of cancer in men. 2020 reported more than 6 lakh cases of esophageal cancer around the world. According to WHO, GLOBOCAN 2018, it is the 6th most common cancer in India, with an incidence rate of 5.04%. In India, it is the 6th common cancer in females and 5th in males.

However, the advancement of medical science has opened new avenues of treatment for esophageal cancer. In the past few years, we saw several techniques and drugs for esophageal cancer cures getting FDA approval. 2022 is no different. Revolutionary immunotherapy for esophageal cancer has created a buzz in oncology. Nivolumab, sold under the brand name Opdivo, Bristol-Myers Squibb Company, got FDA approval on May 27, 2022, as a first-line treatment

Read on to learn more about this new treatment for esophageal cancer

FDA Approves Nivolumab/Chemo and Nivolumab/Ipilimumab

FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) plus chemotherapy and nivolumab plus ipilimumab (Yervoy, Bristol-Myers Squibb Company) as a treatment for patients with advanced or metastatic esophageal cancer. These new cancer cure therapies are especially beneficial for those who cannot undergo esophageal cancer surgery. 


The approval by the FDA was based on the phase 3 CheckMate 648 trial (NCT03143153). In the trial, researchers used nivolumab in combination with ipilimumab or chemotherapy for esophageal cancer. The results showed that patients given nivolumab had better overall survival (OS) than those who only received chemotherapy. 

To give you more clarity, we have mentioned how the study of this new esophageal cancer treatment worked.

More detail about CheckMate 648

Researchers performed CheckMate 648 with 970 randomized patients. All the patients had advanced or metastatic squamous cell carcinoma untreatable through esophagus surgery. There were three categories in the trial. 

  • The first was administered a combination of nivolumab and chemotherapy. 
  • The second group in the trial underwent immunotherapy only and took a combination of nivolumab-ipilimumab. 
  • The third group took only chemotherapy for esophageal cancer

Researchers presented their analysis at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial results showed that the nivolumab-chemotherapy combination conferred longer overall survival (OS) vs. chemotherapy alone among all patients.

Key Findings of the New Treatment & Possible Benefits

  • The two immunotherapy-based combinations are the new hope for many with advanced esophageal cancer
  • It is the world's first treatment regimen without chemotherapy to benefit patients with previously untreated esophageal cancer. Even the combination of nivolumab and ipilimumab significantly prolonged OS against those who took only chemotherapy. 
  • The trial results also showed positive effects in patients with tumor cell PD-L1 expression of 1% or greater. PD-1 is a protein in T cells and plays a significant role in our bodies immune system. When PD-1 binds to another protein called PD-L1, it decreases the ability of T cells to kill cancer cells. Immunotherapy is beneficial in cases where cancer cells have a high amount of PDL1.
  • In the trial CheckMate 648, 48% of the patients in the chemotherapy group and 49% in the combination therapy groups had PD-L1 positive tumors. A follow-up of 13 months showed overall survival was better amongst patients in both combination groups whose tumors were PD-L1 positive. The combination groups also had a percentage of patients whose tumors shrank. 
Treatment GroupAll ParticipantsParticipants with PD-L1+ tumours
Nivolumab + Chemotherapy13.2 months15.4 months
Nivolumab + Ipilimumab12.8 months13.7 months
Chemotherapy alone10.7 months9.1 months

These new therapies can potentially improve the outlook for patients and families affected by esophageal cancer. Such innovation brings us closer to effective, lasting cures for esophageal cancer.


Relevant Blogs

Blog Banner Illustration

Dr. Sandeep Nayak - Best Oncologist in Bangalore

Dr. Sandeep Nayak - Best oncologist in Bangalore. Experience of 19 years. Consults at Fortis, MACS & Ramakrishna. To book an appointment, call @ +91-98678 76979

Blog Banner Image

Eye Cancer Treatment in India ( Know the Best Hospitals, Doctors, Cost And More)

We all agree that eyes are not only one of the most important vital organs but are also important in the appearance of an individual as having beautiful eyes helps with our confidence. Maintaining the health of our eyes is hence very essential, but it has been more and more difficult due to pollution and malnutrition. As a result, the number of Eye cancer cases has been growing over the years, and I would like to provide you with all the information regarding eye cancer. Read on to find more about Eye Cancer Treatment In India.

Blog Banner Image

PET Scan in Mumbai

You’ll find all the available details for the PET scan in Mumbai on this page.

Blog Banner Image

Cancer Treatment in India - Compare Costs, Hospitals & Doctors in 2024

Discover India's world-class cancer treatment options. Get the best care from world-class doctors and hospitals, using the latest technologies and treatments.

Blog Banner Illustration

Organ Specific Cancer Treatment in India

Cancer can occur in all the organs. The treatment plan will differ for different organs based on their site and the intensity of treatment they require. We have further provided the organ specific treatment options for some of the most common types of cancer affecting people all over the world.

Blog Banner Image

Best Medical Tourism Companies in India 2024 List

Discover excellence in healthcare with top-rated Medical Tourism Companies in India. Your journey to world-class treatment begins here.

Blog Banner Image

10 Best Hospitals in Istanbul - Updated 2023

Looking for the best hospital in Istanbul? Here is a compact list for you of the 10 Best Hospitals in Istanbul.

Blog Banner Image

15 Best Places of Hair Donation for Cancer Patients in India

Explore the best places for hair donation for cancer patients in India. Join the meaningful movement with our guide to Hair Donation for Cancer Patients in India, making a positive impact with every strand

Question and Answers

Hi ,my father is diagonsed with DLBCL stage 4 lymphoma, in how many months he will get cured competely

Male | 60

The Diffuse Large B-Cell Lymphoma is treatable and there is no fixed time for complete cure, depending on the stage of the cancer, patient overall health, and the response to treatment.

Answered on 22nd Feb '24

Dr. Ganesh Nagarajan

Dr. Ganesh Nagarajan

There is a lump on my nipple and if I press against it, it hurts

Male | 13

Lumps in the breast may be a sign of breast cancer. You should be evaluated by a professional if you have the pain when you pushing on the lump. But do not panic,need to evaluate for confirmation. Please do not delay

Answered on 21st Feb '24

Dr. Sridhar S

Dr. Sridhar S

Liver cancer many tissue

Male | 60

Yes the liver cancer can spread to other tissues. Some of the most common metastasis sites are the lungs, bones, and lymph nodes. Early diagnosis and management of metastasis are necessary for adequate prevention or control.

Answered on 20th Feb '24

Dr. Sridhar S

Dr. Sridhar S

Cost Of Related Treatments In Country